EyeWorld Weekly, October 3, 2025
➤ Phase 1/2 trial update for Leber congenital amaurosis gene therapy in pediatric patients ➤ Primary endpoint not met in Phase 2b trial investigating persistent corneal epithelial defect treatment ➤ Study: treatment for uveal melanoma could improve survival rate ➤ Company news ➤ ASCRS news and events
Comments Off on EyeWorld Weekly, October 3, 2025
October 3, 2025
